AEON Biopharma, Inc. (AEON)
NYSEAMERICAN: AEON · Real-Time Price · USD
0.564
-0.016 (-2.83%)
Nov 20, 2024, 4:00 PM EST - Market closed

Company Description

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins.

It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder.

The company is based in Irvine, California.

AEON Biopharma, Inc.
AEON Biopharma logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 10
CEO Marc Forth

Contact Details

Address:
5 Park Plaza, Suite 1750
Irvine, California 92614
United States
Phone (949) 354-6499
Website aeonbiopharma.com

Stock Details

Ticker Symbol AEON
Exchange NYSEAMERICAN
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001837607
CUSIP Number 00775E102
ISIN Number US00791X1000
Employer ID 85-3940478
SIC Code 2834

Key Executives

Name Position
Marc Forth Principal Financial Officer, President, Chief Executive Officer and Director
Alex Wilson Executive Vice President, Chief Legal Officer and Corporate Secretary
Dr. Chad K. Oh M.D. Chief Medical Officer
Jennifer Sy Principal Accounting Officer

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 13, 2024 424B3 Prospectus
Nov 13, 2024 10-Q Quarterly Report
Nov 13, 2024 8-K Current Report
Oct 7, 2024 8-K Current Report
Aug 21, 2024 EFFECT Notice of Effectiveness
Aug 21, 2024 424B5 Filing
Aug 19, 2024 UPLOAD Filing
Aug 15, 2024 S-3 Registration statement under Securities Act of 1933
Aug 12, 2024 424B3 Prospectus